Effects of omeprazole and genetic polymorphism of CYP2C19 on the clopidogrel active metabolite

X Boulenc, N Djebli, J Shi, L Perrin, W Brian… - Drug Metabolism and …, 2012 - ASPET
Clopidogrel is an antiplatelet agent widely used in cardiovascular diseases and an inactive
prodrug that needs to be converted to an active metabolite in two sequential metabolic …
被引用次数：44 相关文章

[引用][C] Effects of Omeprazole and Genetic Polymorphism of CYP2C19 on the Clopidogrel Active Metabolite

X Boulenc, N Djebli, J Shi, L Perrin, W Brian… - Drug Metabolism and …, 2011 - cir.nii.ac.jp
Effects of Omeprazole and Genetic Polymorphism of CYP2C19 on the Clopidogrel Active
Metabolite | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …
[PDF] academia.edu

[PDF][PDF] Effects of Omeprazole and Genetic Polymorphism of CYP2C19 on the Clopidogrel Active Metabolite□ S

X Boulenc, N Djebli, J Shi, L Perrin, W Brian… - DRUG METABOLISM …, 2012 - academia.edu
Clopidogrel is an antiplatelet agent widely used in cardiovascular diseases and an inactive
prodrug that needs to be converted to an active metabolite in two sequential metabolic …
[PDF] researchgate.net

[PDF][PDF] Effects of Omeprazole and Genetic Polymorphism of CYP2C19 on the Clopidogrel Active Metabolite□ S

X Boulenc, N Djebli, J Shi, L Perrin… - DRUG METABOLISM …, 2012 - researchgate.net
Clopidogrel is an antiplatelet agent widely used in cardiovascular diseases and an inactive
prodrug that needs to be converted to an active metabolite in two sequential metabolic …

Effects of Omeprazole and Genetic Polymorphism of CYP2C19 on the Clopidogrel Active Metabolite

X Boulenc, N Djebli, J Shi, L Perrin, W Brian… - Drug Metabolism and …, 2011 - ASPET
Clopidogrel is an antiplatelet agent widely used in cardiovascular diseases and an inactive
prodrug that needs to be converted to an active metabolite in two sequential metabolic …

Effects of omeprazole and genetic polymorphism of CYP2C19 on the clopidogrel active metabolite

X Boulenc, N Djebli, J Shi, L Perrin, W Brian… - 2012 - pubmed.ncbi.nlm.nih.gov
Clopidogrel is an antiplatelet agent widely used in cardiovascular diseases and an inactive
prodrug that needs to be converted to an active metabolite in two sequential metabolic …
[PDF] psu.edu

[PDF][PDF] Running title page Running title: Clopidogrel: omeprazole effect and CYP2C19 polymorphism Address correspondence to

X Boulenc - 2011 - Citeseer
Clopidogrel is an antiplatelet agent widely used in cardiovascular diseases and an inactive
prodrug that needs to be converted to an active metabolite in two sequential metabolic …

Effects of omeprazole and genetic polymorphism of CYP2C19 on the clopidogrel active metabolite.

X Boulenc, N Djebli, J Shi, L Perrin, W Brian… - Drug Metabolism and …, 2011 - europepmc.org
Clopidogrel is an antiplatelet agent widely used in cardiovascular diseases and an inactive
prodrug that needs to be converted to an active metabolite in two sequential metabolic …
[PDF] psu.edu

[PDF][PDF] Effects of Omeprazole and Genetic Polymorphism of CYP2C19 on the Clopidogrel Active Metabolite□ S

X Boulenc, N Djebli, J Shi, L Perrin, W Brian… - DRUG METABOLISM …, 2012 - Citeseer
Clopidogrel is an antiplatelet agent widely used in cardiovascular diseases and an inactive
prodrug that needs to be converted to an active metabolite in two sequential metabolic …
[PDF] academia.edu

[PDF][PDF] Effects of Omeprazole and Genetic Polymorphism of CYP2C19 on the Clopidogrel Active Metabolite□ S

X Boulenc, N Djebli, J Shi, L Perrin, W Brian… - DRUG METABOLISM …, 2012 - academia.edu
Clopidogrel is an antiplatelet agent widely used in cardiovascular diseases and an inactive
prodrug that needs to be converted to an active metabolite in two sequential metabolic …